Molecular Targeted Approaches for Advanced BRAF V600, N-RAS, c-KIT, and GNAQ Melanomas

Table 1

Patients treated with BRAF and NRAS inhibitors.

Patient ID	Gender	Age	Treatment duration (months)	Objective response	Time to progression (months)	Followup (months)	Status
1	F	60	6	Partial	6	18	Dead
2	F	61	26	In response	26	29	Alive
3	F	66	4	Partial	4	13	Dead
4	F	51	14	Partial	14	19	Alive
5	M	59	4	Partial	4	5	Dead
6	F	67	6	Partial	6	7	Dead
7	M	51	6	Partial	6	18	Alive
8	M	70	6	Partial	6	11	Dead
9	F	68	23	Partial	In response	23	Alive
10	F	62	6	Partial	6	11	Alive
11	F	81	8	Partial	7	8	Dead
12	M	56	2	None	3	3	Dead
13	F	51	5	Partial	5	5	Dead
14	F	58	18	Partial	In response	18	Alive
15	M	68	6	Partial	14	6	Dead
16	M	43	9	Partial	3	16	Dead
17	M	62	6	Partial	In response	6	Alive
18	M	58	8	Partial	In response	18	Dead
19	M	38	2	Partial	2	3	Dead
20	M	66	12	Partial	10	12	Alive
21	M	65	6	Partial	In response	6	Alive
22	M	79	7	In response	Stable disease	7	Alive
23	M	75	8	Partial	6	8	Dead
1 N-ras	M	69	10	Partial	10	12	Alive
2 N-ras	M	56	6	Stable	6	7	Alive